Demography, clinical and laboratory features of systemic sclerosis in a Malaysian Rheumatology Centre

Medical Journal of Malaysia

Volumn 62, Issue 2, 2007, Pages 117-121

  Pagalavan, Letchumanan ^a,b   Ong, S G ^a  

^a Selayang Hospital   (Malaysia)

^b NONE   (Malaysia)

Author keywords

Diffuse cutaneous systemic sclerosis; Limited cutaneous systemic sclerosis; Raynaud's; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; SCL 70 ANTIBODY;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CALCINOSIS; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GANGRENE; GASTROESOPHAGEAL REFLUX; HUMAN; INDIAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MYOSITIS; ONSET AGE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCLERODERMA; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TELANGIECTASIA;

EID: 34547631790     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr, TA Rowell N, Wollheim F. Scleroderma (SSc) : Classification subsets and pathogenesis. J Rheumatol 1998; 15: 202-5.
2. Medsger Jr., TA Steven VD. Systemic sclerosis (scleroderma) : Clinical aspect. In: Koopman WJ, ed. Arthritis and allied conditions. A textbook of rheumatology. Vol 2. Philadelphia: Williams & Wilkins, 1997; 1433-65.
3. Medsger Jr, TA Steven VD. Classification and prognosis. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Philadelphia: Williams & Wilkins, 1996; 51-64.
4. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Raveille JD. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma. Arthritis Rheum 1996; 39: 1362-70.
5. Steen VD, Medsger Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
6. Govet D, Azais I, Marechaud R, Alcalay M, Barriere H, Bantoux D, Sudre Y. Prognosis of generalized scleroderma . A retrospective study of 78 cases. Rev Med Interne 1986; 7: 233-41.
7. Meyer O. Clinical, serological and immunogenetic studies of systemic sclerosis: A French response to the paper of PJ Maddison. Rev Rhum 1991; 58: 371-3.
8. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
9. Satoh M, Akizuki M, Kuwana M, Mimori T, Yomagata H, Yashida S, Homma M, Yamamoto T, Sasazuki T. Genetic and immunological differences between Japanese patients with diffuse and limited scleroderma. J Rheumatol 1994; 21: 111-4.
10. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classifications in the early stages of the disease. J Rheumatol 1988; 15: 276-83.
11. Lee P, Lengevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in SSc (scleroderma). QJ Med 1992; 82: 139-48.
12. Scussel-Lonzetti, Lilian, Joyal, Raynauld JP, Roussin A, Rich E, Goulet JR, Raymond, Yves, Senecal JL. Predicting Mortality in Systemic Sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81: 154-67.
13. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G. Systemic Sclerosis: Demographic, Clinical and serologic features and survival in 1,012 Italian Patients. Medicine 2002; 81(2): 139-53.
14. Subcommittee for Scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
15. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
16. Della Rossa A, Valentini G, Bombardieri W et al. European multicentre study to define disease activity for systemic sclerosis : Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 585-91.
17. Steen VD, Powell DL, Medsger TA Jr et al. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
18. Kuwana M, Kaburaki J, Okano Y et al. Clinical and prognostic association on serum antinuclear antibody in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
19. Chandran G, Ahern MJ, Smith M et al. A study of scleroderma in South Australia: prevalence, subset, characteristic and nailfold capillaroscopy. Aust NZ Med 1995; 25: 688-94.
20. Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16: 454-60.
21. Jacobsen S, Halberg P, Ullman S et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998; 37: 39-45.
22. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine 1980; 59: 393.
23. Salerni R, Rodnan GP, Leon DF et al. Pulmonary hypertension in the CREST Syndrome variant of progressive Systemic sclerosis (scleroderma). Ann Intern Med 1977; 53: 1.
24. Schurawitzki H, Stiglbauer R, Graninger W et al. Insterstitial lung disease in progressive systemic sclerosis: high-resolution T versus radiography. Radiology 1990; 176(3): 755-9.
25. Griedinger EL, Flaherty KT, White B et al. African American race and antibodies to topoisomerase-I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801-7.
26. Steen VD, Conte C, Owens GR et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37(9): 1283-9.
27. Kuwana M, Kaburaki J, Arnett FC et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999; 42(3): 465-74.
28. Altman RD, Medsger Jr, TA Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
29. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis. Br J Rheum 1998; 37: 750-5.
30. Tan EM, Rodnan GP, Garcia I et al. Diversity of antinuclear antibodies in progressive systemic sclerosis : Anticentromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23: 617.
31. Reveille JD, Solomom DH. American College of Rheumatology, ad hoc committee on Immunologic Testing Guidelines: Evidence based guidelines for the use of immunologic tests: anticentromere, Sc170 and nucleolar antibodies. Arthritis Rheum 2003; 49: 399-412.
32. Hesselstrand R, Scheja A, Shen GQ et al. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-40.
33. Munves EF, Schur PH. Antibodies to Sm and RNP: Prognosticaters of disease involvement. Arthritis Rheum 1983; 26: 848.
34. Reveille JD, Fischbach M, McNearney T et al. Systemic sclerosis in 3 US ethnic group: a comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Senin Arthritis Rheum 2001; 30: 332-46.
35. Kameda H, Kuwana M, Hama N et al. Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. J Rheumatol 1997; 24: 400-403.
36. Sharp GC, Irvin WS, May CM. Association of autoantibodies to ribonucleoprotein and Sm antigens with mixed connective tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295: 1149-154.
37. Ginsburg WW, Conn DL, Bunch TW et al. Comparison of clinical and serologic markers in SLE and overlap syndrome: A review of 247 patients. J Rheumatol 1983; 10: 235.